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Hepatocellular carcinoma (HCC) is the third cause of cancer-related death worldwide. Unfortunately, the incidence and mortality
associated with HCC are increasing.Therefore, new therapeutic strategies are urgently needed and the use of mesenchymal stromal
cells (MSCs) as carrier of therapeutic genes is emerging as a promising option. Different sources of MSCs are being studied for
cell therapy and bone marrow-derived cells are the most extensively explored; however, birth associated-tissues represent a very
promising source.The aimof thisworkwas to compare the in vitro and in vivomigration capacity between bonemarrowMSCs (BM-
MSCs) and human umbilical cord perivascular cells (HUCPVCs) towards HCC. We observed that HUCPVCs presented higher in
vitro and in vivo migration towards factors released by HCC. The expression of autocrine motility factor (AMF) receptor, genes
related with the availability of the receptor on the cell surface (caveolin-1 and -2) and metalloproteinase 3, induced by the receptor
activation and important for cell migration, was increased in HUCPVCs. The chemotactic response towards recombinant AMF
was increased in HUCPVCs compared to BM-MSCs, and its inhibition in the conditioned medium from HCC induced higher
decrease in HUCPVCmigration than in BM-MSC. Our results indicate that HUCPVCs could be a useful cellular source to deliver
therapeutic genes to HCC.
1. Introduction
Hepatocellular carcinoma (HCC) is one of the leading causes
of cancer-related death worldwide. At early stages of the
disease only a small fraction of patients are amenable to
curative treatments that include surgical resection, liver
transplantation, or radiofrequency ablation [1]. For patients
with advanced HCC, the multikinase inhibitor sorafenib
shows limited survival benefits in comparison with placebo
[2]. Thus, the development of new therapeutic approaches
is critical, and cellular therapy emerges as a new potential
strategy to deliver therapeutic genes to HCC.
Mesenchymal stromal cells (MSCs) constitute a heteroge-
neous population of cells that include adult multipotent cells
[3]. MSCs are present in adult tissues and their involvement
in repair mechanisms has been demonstrated as the result of
their ability to migrate towards sites of injury, their capacity
to differentiate into tissues ofmesodermal origin (adipocytes,
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osteoblasts, and chondroblasts), and their immunoregulatory
properties [4]. Moreover, the possibility of easily expanding
these cells in vitro makes them useful tools for therapeutic
use in regenerative medicine, immunomodulation purposes
and also as cellular carriers for therapeutic genes [5].
MSCs can be isolated fromdifferent tissues. Among them,
bone marrow- (BM-) derived stromal cells were the first
described and are the most frequently used [6]. However, the
requirement of invasive methods to obtain BM-MSCs is in
support of using alternative sources such as adipose tissue,
peripheral blood, and dental pulp [7]. In addition to these
adult tissues, MSCs can be obtained from birth-associated
tissues including placenta, amnion, and umbilical cord with
the advantage of their availability avoiding the need of
invasive procedures and eliminating other ethical concerns.
Different types of MSCs have been obtained from the umbil-
ical cord depending on if they were isolated from the whole
umbilical cord (UC-MSCs), Wharton’s Jelly (WJ-MSCs), the
umbilical cord blood (CB-MSCs) [8], or perivascular areas
(human umbilical cord perivascular cells, HUCPVCs) [9].
In particular, HUCPVCs may be advantageous candidates
for cell therapy due to their lower donor variability, faster
doubling time, and ready availability [10].
It has been demonstrated that MSCs from different
sources display similar phenotypic and cytological charac-
teristics [11–13]; however, differences in their functional role
have also been previously described. For instance, BM and
WJ-derived MSCs have different proliferative capacity [11]
and secretome and proteomic profiles [14, 15].
The establishment and spread of a tumor is a process
that involves a complex cross-talk between cancer cells and
the tumor microenvironment. HCC cells were found to be
modulated by the tumor milieu through the secretion of
several factors, and the tumor cells modify their microen-
vironment in order to promote their own growth [16]. Par-
ticularly, MSCs express receptors for various cytokines and
chemokines allowing them to migrate towards HCC tumors
[17].Thus, recruitment ofMSCs to cancer microenvironment
is likely mediated by the interaction of cytokines/chemokines
and their specific receptors. As an example, it has been
demonstrated that CXCR1 is involved in UC-MSCmigration
towards glioma [18] and that overexpression of CXCR1 [19] or
CXCR4 in these cells [20] increases their homing into tumors.
In addition, MSCs were engineered to express cytotoxic
cytokines for treatment of lung tumors and non-Hodgkin’s
lymphomas [21, 22]. Thus, the possibility of increasing
MSC migratory capacity and engraftment into tumors could
enhance beneficial effects of therapeutic genes.
The aim of this work was to compare HUCPVCs and
the “gold standard” BM-MSCs migratory capacity towards
factors released from HCC and to analyze mechanisms
therein involved.
2. Materials and Methods
2.1. Cell Lines. Human HCC cell line HuH7 was kindly pro-
vided byProfessor Jesus Prieto (CIMA,University ofNavarra,
Pamplona, Spain) [23]. LX-2 cell line (human hepatic stellate
cells generated by spontaneous immortalization in low serum
conditions) was kindly provided by Dr. Scott Friedman
(Division of Liver Diseases, Mount Sinai School of Medicine,
New York, NY, USA) [24]. Human microvascular endothe-
lial cells (HMEC-1) were from CDC (Centers for Disease
Control, Atlanta, GA, USA) and WI-38 (human fibroblast
cell line) from the American Type Culture Collection. Cell
lines were cultured in complete DMEM (2 𝜇M glutamine,
100U/mLpenicillin, 100mg/mL streptomycin) and 10%heat-
inactivated fetal bovine serum (FBS). Primary culture of
HCC cells (HC-PT-5) was previously generated in our lab-
oratory [25]. The collection of the sample and the project
was approved by the Institutional Evaluation Committee
(CIE) from School of Biomedical Sciences, Austral University
(Protocol no. 11-007), and written informed consent was
obtained from the patient. HC-PT-5 was cultured up to 8
passages in 70% DMEM/30% F12 (Invitrogen/Life Technolo-
gies) culture medium supplemented with 2 𝜇M glutamine,
100U/mL penicillin, 100mg/mL streptomycin, and 10%
FBS.
2.2. Isolation of BM-MSCs and HUCPVCs. BM-MSCs were
obtained from healthy donors (Hospital Naval Pedro Mallo,
Buenos Aires, Argentina) as described previously [25].
HUCPVCs were isolated from umbilical cord obtained
from healthy donors at the Hospital Universitario Austral
(Pilar, Buenos Aires, Argentina) using a protocol adapted
from Sarugaser et al. [9]. In brief, umbilical cords were
dissected and vessels with their surrounding Warthon’s
Jelly were pulled out. The perivascular mesenchymal tissue
was removed from the vessels and mechanically disrupted.
Minced fragments were plated in complete DMEM low
glucose/20%FBS (Internegocios S.A., Argentina). After 7-day
incubation, nonadherent cells and minced fragments were
removed and adherentHUCPVCswere cultured and used for
different experiments at passages 4 to 6.
MSCs were characterized according to the International
Society for Cellular Therapy (ISCT) guidelines [26]. Pheno-
type characteristics ofMSCs were determined by flow cytom-
etrywith anti-humanPE conjugated antibodies against CD14,
CD34, CD44, CD73, CD90, and CD105 (BD Biosciences)
for 30min. Samples were analyzed using a FACSCalibur
flow cytometer (Becton Dickinson), and data acquired were
analyzed using Cyflogic software (CyFlo Ltd.).
2.3. Conditioned Medium. To obtain tumor conditioned
medium (TCM), HuH7 cells (2 × 106) or HC-PT-5 cells (5
× 106) were inoculated subcutaneously (s.c.) into the right
flank of nude mice. When tumors reached 200mm3 in size
approximately, tumors were dissected andminced into pieces
smaller than 1mm3 and transferred to a 24-well tissue culture
plate (6 fragments/well) with 500 𝜇L of complete DMEM
without FBS. Cell conditioned medium (CCM) was obtained
from cell lines cultured as described above. Then, cells that
reached a 90% of confluence were washed with PBS and
cultured with complete DMEM without FBS. In both cases,
18 hours later, conditioned media were harvested and stored
at −80∘C until use.
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2.4. In Vitro Migration Assays. In vitro migration was per-
formed using a 48-Transwell microchemotaxis Boyden
Chamber unit (Neuroprobe, Inc.) as previously described
[25]. MSCs (1.2 × 103 cells/well) were placed in the upper
chamber and DMEM, CCM, TCM, or rAMF were applied
to the lower chamber of the transwell unit. For blocking
experiments, TCM were preincubated for 60min with anti-
AMF antibody or isotype control IgG. All systems were left at
37∘C in a 5% CO
2
humidified atmosphere for 4 hours except
for experiments involving rAMF that were maintained for
18 hours. Cells attached to the lower side of the membrane
were fixed in 2% formaldehyde, stained with 4󸀠,6-diamidino-
2-phenylindole dihydrochloride (DAPI, Sigma-Aldrich), and
counted using fluorescent-fieldmicroscopy at 100x. Captured
images from three representative visual fields were analyzed
using Cell Profiler software (http://www.cellprofiler.com/)
and the mean number of cells/field ± SEM was calculated.
2.5. Cell Adhesion Assays. For analyses of MSC adhesion
to endothelial cells, 2 × 105 HMEC-1 were seeded in 96-
well microplates and cultured for 1 day prior to the assay.
Coated wells were incubated for 5 minutes with 0.1mL
of 5 × 104 cells/mL of Fast-DiO prelabelled MSCs. Cell
suspension was discarded and attached cells were fixed with
2% paraformaldehyde. Cells were counted using fluorescent-
field microscopy at 200x: pictures taken from ten represen-
tative visual fields were analyzed using Cell Profiler soft-
ware (http://www.cellprofiler.com/) and the mean number of
cells/field ± SEM was calculated.
2.6. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). Total RNA of MSCs was extracted using Trizol
Reagent (Sigma-Aldrich Co., St. Louis, MO). Total RNA
(4 𝜇g) was reverse-transcribed with 200U of SuperScript
II Reverse Transcriptase (Invitrogen, Carlsbad, CA) using
500 ng of Oligo (dT) primers. cDNAs were subjected to
real-time polymerase chain reaction (qPCR) (Stratagene
Mx3005p, Stratagene, La Jolla, CA, USA). For qRT-PCR,
the mRNA levels of CXCR1, CXCR2, CCR2, IL-6 receptor
(IL-6R), IL-6 signal transducer (IL-6ST), AMF receptor
(AMFR), metalloproteinase 3 (MMP3), insulin-like growth
factor-binding protein 3 (IGFBP3), caveolin-1 (CAV-1), and
caveolin-2 (CAV-2) were quantified by SYBR Green (Invitro-
gen), using the following primers: CXCR1 forward 5󸀠-TTT-
TCCGCCAGGCTTACCAT-3󸀠 and reverse 5󸀠-AACACC-
ATCCGCCATTTTGC-3󸀠; CXCR2 forward 5󸀠-TAAGTG-
GAGCCCCGTGGGG-3󸀠 and reverse 5󸀠-TGGGCTCAG-
GGGCAGGATG-3󸀠; CCR2 forward 5󸀠-CGAGAGCGG-
TGAAGAAGTCA-3󸀠 and reverse 5󸀠-AGCATGTTGCCC-
ACAAAACC-3󸀠; IL-6R forward 5󸀠-GCACTTGCTGGT-
GGATGTTC-3󸀠 and reverse 5󸀠-AGCCTTTGTCGTCAG-
GGATG-3󸀠; IL-6ST forward 5󸀠-CCCACCTCATGCACT-
GTTGA-3󸀠 and reverse 5󸀠-TTATGTGGCGGATTCGGCTT-
3󸀠; AMFR forward 5󸀠-ACAAGATGTGGGCCTTGCAAG-
A-3󸀠 and reverse 5󸀠-AAAACGCAGTGCTCCCAGGATA-
3󸀠; MMP3 forward 5󸀠-ACGCCAGCCAACTGTGATCCT-
3󸀠 and reverse 5󸀠-ATATGCGGCATCCACGCCTGAA-3󸀠;
IGFBP3 forward 5󸀠-ACTGTGGCCATGACTGAG-3󸀠 and
reverse 5󸀠-AGAGTCTCCCTGAGCCTGA-3󸀠; CAV-1 for-
ward 5󸀠-AATCCAAGCATCCCTTTGCCCA-3󸀠 and reverse
5󸀠-ACCAGGCAGCTTTCTGTACGA-3󸀠; CAV-2 forward
5󸀠-GAGAGACAGGGGAGTTGTCAACTT-3󸀠 and reverse
5󸀠-GCCCGGCCCAGAAATAATGAGAT-3󸀠. PCR ampli-
fications were carried out using a cycle of 95∘C for 10 minutes
and 45 cycles under the following parameters: 95∘C for 30
seconds, 58∘C for 60 seconds, 72∘C for 30 seconds. At the end
of PCR reaction, the temperature was increased from 60∘C to
95∘C at a rate of 2∘C/min, and the fluorescence was measured
every 15 seconds to construct the melting curve. Values were
normalized to levels of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH; used as housekeeping) transcript (for-
ward 5󸀠-CATCTCTGCCCCCTCTGCTG-3󸀠 and reverse 5󸀠-
GCCTGCTTCACCACCTTCTTG-3󸀠). Data were processed
by theΔΔCtmethod.The relative amount of the PCR product
amplified fromBM-MSCswas set as 1. A nontemplate control
(NTC) was run in every assay, and all determinations were
performed as triplicates in three separated experiments.
2.7. Mice and In Vivo Experiments. Six- to eight-week-
old male nude mice (Nu/Nu) were purchased from CNEA
(Comisio´n Nacional de Energı´a Ato´mica, Ezeiza, Buenos
Aires, Argentina). Subcutaneous HuH7 tumors (2 × 106cells)
were established and 10 days later BM-MSCs or HUCPVCs
were intravenously (i.v.) injected. Tumor growthwas assessed
by calliper measurement, and tumor volume (mm3) was
calculated by the formula 𝜋/6 × larger diameter × (smaller
diameter)2. For in vivo migration studies, MSCs (5 × 105)
were prelabeled with CM-DiI for histological analysis and
DiR (Molecular Probes, Invitrogen) for fluorescence imag-
ing (FI). FI was performed using the Xenogen In Vivo
Imaging System (IVIS; Caliper Life Sciences, Hopkinton,
MA, USA) 1 hour after MSC injection and every day until
experimental end point. At day 3 mice were sacrificed
and isolated tissues were exposed to FI. Images represent
the radiant efficiency and were analyzed with IVIS Living
Image (Caliper Life Sciences) software. Regions of inter-
est (ROI) were automatically drawn around the isolated
organs to assess the fluorescence signal emitted. For the
total signal present in mice, results were expressed as total
radiant efficiency in units of photons/second within the
region of interest [p/s]/[𝜇W/cm2]. Signal present in tumor,
liver, spleen, or lungs was expressed as percentage of total
signal.
2.8. Detection of BM-MSCs by Fluorescence. To detect CM-
DiI+ cells within tumors, frozen sections were mounted in
mounting media with DAPI (Vector Laboratories, Inc.) and
observed under a fluorescence microscope at 200x.
2.9. Statistical Analyses. Unpaired 2-sided Student’s 𝑡-test and
one-way analysis of variance followed by posttests orKruskal-
Wallis and Dunn’s posttests (GraphPad Prism Software) were
used for statistical analyses. 𝑃 values lower than 0.05 were
considered as statistically significant.
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Figure 1: Characterization of BM-MSCs andHUCPVCs. (a) Flow cytometry analysis of cell surfacemarkers of both types ofMSCs. Grey area
indicates background fluorescence with IgG isotype control. One representative experiment is shown. (b) In vitro migration of BM-MSCs
(black bars) or HUCPVCs (grey bars) towards CCM from HCC (HuH7 and HC-PT-5), hepatic stellate cells (LX-2), fibroblasts (WI-38),
or endothelial cells (HMEC-1). Bars represent the average of MSCs/field (10x) ± SEM from three representative visual fields. Results are
representative of 3 independent experiments. #𝑃 < 0.001 versus DMEM; ∗∗∗𝑃 < 0.001 versus BM-MSCs. (c) Adhesion towards endothelial
cells of BM-MSCs (black bars) or HUCPVCs (grey bars). Results are representative of 3 independent experiments. ∗∗∗𝑃 < 0.001 versus
BM-MSCs.
3. Results
3.1. Characterization of BM-MSCs and HUCPVCs. In accor-
dance with the criteria for definingMSCs of the International
Society for Cellular Therapy (ISCT) [26], surface marker
expression of BM-MSCs and HUCPVCs was evaluated by
flow cytometry. Both types of MSCs showed similar pheno-
typic characteristics and were found to express CD73, CD90,
CD105, and CD44 but not to express the hematopoietic
markersCD14,CD34, orCD79 (Figure 1(a)).Wenext decided
to evaluate the in vitro migration capacity of MSCs towards
cell culture conditioned media (CCM) obtained from HCC
cell lines (HuH7 and HC-PT-5), hepatic stellate cells (LX-
2), fibroblasts (WI-38), and endothelial cells (HMEC-1).
Interestingly, a higher migratory capacity towards all the
CCM was found for HUCPVCs when compared to BM-
MSCs (Figure 1(b)). Moreover, in contrast to our previous
results observed with BM-MCSs [25], HUCPVCs showed
capability to migrate to CCM derived from nontumoral
components (fibroblast and endothelial cells). Besides their
capacity to migrate toward factors secreted by HCC, the
arrest of MSCs within the microvasculature is considered a
critical step for an efficient homing and anchorage to tumors.
Therefore, we next decided to evaluate adhesion ability of
MSCs and observed that HUCPVCs showed an increased in
vitro adhesion to HMEC-1 endothelial cells in comparison
with BM-MSCs (Figure 1(c)).
3.2. In Vivo Migration of BM-MSCs and HUCPVCs towards
HCC. To further characterize MSC behavior in vivo, non-
invasive migration assay was performed. CM-DiI and DiR
prelabelled BM-MSCs or HUCPVCs were i.v. injected in
HCC tumor-bearing mice in order to evaluate MSC recruit-
ment. Similar to our previous observation with BM-MSCs
[25], at 3 days after cell transplantation a positive signal corre-
sponding to HUCPVCs was found in liver, lungs, spleen, and
s.c. tumors (Figure 2(a)). Despite the fact that total signal was
BioMed Research International 5
5.0
4.0
3.0
2.0
1.0
×108
Ra
di
an
t e
ffi
ci
en
cy
(p
/s
/c
m
2
/s
r)
/(
𝜇
W
/c
m
2
)
(a)
∗∗∗
BM-MSCs
HUCPVCs
BM-MSCs HUCPVCsT
ot
al
 ra
di
an
t e
ffi
ci
en
cy
 (p
/s
)/
 (𝜇
W
/c
m
2
) ×1013
2.4
2.3
2.2
2.1
2.0
1.9
1.8
1.7
1.6
1.5
1.4
(b)
BM-MSCs HUCPVCs
5.0
4.0
3.0
2.0
1.0
×108
Ra
di
an
t e
ffi
ci
en
cy
(p
/s
/c
m
2
/s
r)
/(
𝜇
W
/c
m
2
)
(c)
BM-MSCs
HUCPVCs
To
ta
l s
ig
na
l (
%
) 90
80
8
6
4
2
0
Liver Lung Spleen Tumor
∗
∗
(d)
DAPI CM-DiI
(e)
BM-MSCs
HUCPVCs
250
200
150
100
50
0
HuH7 HC-PT-5
N
um
be
r o
f c
el
ls/
fie
ld
∗∗∗
∗∗∗
(f)
Figure 2: In vivomigration of BM-MSCs and HUCPVCs. CM-DiI and DiR prelabeled MSCs were i.v. injected in s.c. HuH7 tumor-bearing
mice. At day 3 mice were sacrificed and organs were removed; lungs, livers, spleen (a) and tumors (c) were exposed to obtain FI. Images
represent the radiant efficiency. Representative images are shown. (b) Total FI for injected BM-MSCs or HUCPVCs was calculated by
measuring the region of interest (ROI) for all the tissues isolated and results were expressed as total radiant efficiency [p/s]/[𝜇W/cm2].
∗∗∗
𝑃 < 0.001. (d) Signal present in the isolated liver, spleen, lungs and tumors was represented as percentage of total signal for BM-MSCs or
HUCPVCs-injected mice. ∗𝑃 < 0.05 versus BM-MSCs. (e) Microscopic analysis of transplanted CM-DiI-labeled MSCs (red signal indicated
by arrows) andDAPI staining in frozen sections of tumors. ×200magnification. (f) In vitromigration ofMSCs to TCMderived fromHuH7 or
HC-PT-5 s.c. tumors. Bars represent the average of MSCs/field (10x) ± SEM from three representative visual fields. Results are representative
of 3 independent experiments. ∗∗∗𝑃 < 0.001 versus BM-MSCs.
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Figure 3: Differential expression of cytokines/chemokines receptors and AMF/AMFR pathway in MSCs. Expression of cytokines and
chemokines receptors (a) and AMF/AMFR axis proteins (b) was evaluated in BM-MSCs (black bars) or HUCPVCs (grey bars) by qPCR.
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lower in mice injected with HUCPVCs compared to those
injected with BM-MSCs (Figure 2(b)), the percentage of total
signal corresponding to s.c. tumor locations was increased
in mice administered with HUCPVCs in comparison with
animals that received BM-MSCs (Figures 2(c) and 2(d)),
indicating an enhanced engraftment of HUCPVCs into HCC
tumors. In the other evaluated tissues, signal intensity was
similar for BM-MSC or HUCPVCs in lung and liver and
it was comparatively reduced in the spleen of HUCPVCs-
injected mice (Figure 2(d)). Presence of MSCs in the s.c.
tumors was also confirmed by fluorescence microscopy
(Figure 2(e)). Finally, we evaluated whether MSCs might
present differential migratory capacity towards CM obtained
from s.c. tumors (TCM). Interestingly, a greater in vitro
migratory capacity towards TCM from HCC was observed
for HUCPVCs when compared to BM-MSCs (Figure 2(f)).
3.3. AMFR Was Highly Expressed in HUCPVCs. In order
to evaluate mechanisms partially explaining the differential
migratory capacity of HUCPVCs compared to BM-MSCs
towards tumor released factors, we analyzed the expression
of some chemokine’s receptor likely involved inMSC recruit-
ment towards HCC. Taking into account several reports
demonstrating that interleukin- (IL-) 8, GRO, chemokine
(C-C motif) ligand (CCL)-2, and IL-6 are among the most
relevant factors in HCC [17], we decided to evaluate by qPCR
the expression of CXCR1, CXCR2, CCR2, IL-6R, and IL-
6ST. Interestingly, constitutive CXCR1 and CXCR2 mRNA
expression was found to be lower and CCR2 slightly higher
in HUCPVCs when compared to BM-MSCs, while IL-6R
and IL-6ST expression was similar in both MSCs sources
(Figure 3(a)). Next, we decided to evaluate the axis of the
autocrinemotility factor (AMF), a cytokine with chemotactic
effect on MSCs as recently observed by our group [27].
By qPCR, a significantly higher expression of the AMF
receptor (AMFR) was found in HUCPVCs when compared
to BM-MSCs. Similarly, genes known to be related to the
availability of the receptor in the cell surface such as caveolin-
1 (CAV-1) and caveolin-2 (CAV-2) were also highly expressed
in HUCPVCs as well as the metalloproteinase 3 (MMP3),
necessary to the transmigration process. In contrast, expres-
sion levels of insulin-like growth factor-binding protein 3
(IGFBP3), a protein that negatively regulates AMF/AMFR
pathway, were found to be reduced in HUCPVCs when
compared to BM-MSCs (Figure 3(b)).
3.4. HUCPVCs Displayed Enhanced Migration towards AMF
In Vitro. We have previously demonstrated that AMF, a
cytokine produced by HCC cells, plays a critical role in
MSC migration [27]. Due to the increased AMFR and AMF-
AMFR-related proteins expression in HUCPVCs, we decided
to test the in vitro migration response to the recombinant
AMF (rAMF) of both types ofMSCsusing a chemotaxis assay.
A significantly higher migration to different doses of rAMF
(0.5 and 0.75 𝜇g/mL) was observed for HUCPVCs when
compared to BM-MSCs (Figure 4(a)). In spite of different
types of MSCs showing similar reduction in migration levels
(50% of control) towards HuH7 TCM after the blockage with
anti-AMF antibody (data not shown), preincubation of HC-
PT-5 TCM with anti-AMF antibody (AMF-ab) resulted in
a further reduction in HUCPVCs migration capacity (54%
of control) when compared to BM-MSCs (67% of control)
(Figure 4(b)).
4. Discussion
The aim of this study was to assess the capability of different
sources of MSCs to migrate towards HCC released factors
in order to select those showing higher tumor recruitment
capacity for future therapeutic applications. Our results
indicated that although both types of MSCs share simi-
lar phenotypic characteristics as MSCs, HUCPVCs have a
higher potential to migrate in vitro towards the conditioned
medium derived not only from HCC cells, but also from
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Figure 4: HUCPVCs showed enhanced migration towards AMF in comparison with BM-MSCs. (a) In vitromigration of BM-MSCs (black
bars) or HUCPVCs (grey bars) towards rAMF. #𝑃 < 0.05 versus DMEM (0 𝜇g/mL rAMF); ∗𝑃 < 0.05 versus BM-MSCs. (b) In vitromigration
of BM-MSCs (black bars) or HUCPVCs (grey bars) towards HC-PT-5 TCM preincubated with anti-AMF antibody (AMF-ab) or control
isotype (IgG-ab) was evaluated. #𝑃 < 0.05 versus IgG-ab; ∗𝑃 < 0.05 versus BM-MSCs. Bars represent the average of MSCs/field (10x) ± SEM
from three representative visual fields. Results are representative of 3 independent experiments.
nontumoral components of the tumor microenvironment
like activated hepatic stellate cells (LX-2), fibroblasts (WI-
38), or tumor microendothelial cells (HMEC-1). Moreover,
HUCPVCs also showed an enhanced adhesion capacity
to HMEC-1 cells compared to BM-MSCs. This enhanced
adhesion to endothelial cells could allow a more efficient
arrest in tumor microvasculature which is a required step for
MSC recruitment into HCC. In line with this, we observed
that HUCPVCs also exhibited greater migration capacity in
vivo towards experimental HCC. In contrast to that observed
in the in vitro migration experiments, HUCPVCs showed a
similar migration capability towards nontumoral tissues like
liver or lung and also showed a lower recruitment to the
spleen. AlthoughHUCPVCsmigrated better than BM-MSCs
toward activated hepatic stellate cells in vitro, no differences
were observed in in vivo migration to normal liver, where
hepatic stellate cells are quiescent. In addition, it should be
noted that mice injected with HUCPVCs showed a lower
total signal than those injected with BM-MSCs, probably
due to differences in the DiR uptake for both kinds of cells
or in the number of inoculated cells. These results are in
agreement with previous works showing that MCSs derived
from umbilical cord are able tomigrate towards experimental
tumors such as glioma [28], breast cancer [29], and lung ade-
nocarcinoma [30]. Nonetheless, to the best of our knowledge,
this is the first report describing the comparative migration
capacity of human umbilical cord perivascular cells towards
human HCC.
Tumor-homing is thought to be mediated by interactions
of cytokines/chemokines with their specific receptors. A
number of cytokines, growth factors, and chemokines are
secreted by HCC cells and their microenvironment [17]. We
have recently found that AMF is critical for MSC migration
toward HCC in vitro and in vivo. Furthermore, other factors
released by tumor stroma components like IL-8, GRO, IL-6,
or CCL-2 could also be involved inMSC recruitment toHCC.
Thus, differences observed between HUCPVCs and BM-
MSCs in their in vitro and in vivomigration capacity towards
HCC seem at least partially related to differences in the
expression of cytokine/chemokine receptors. Some studies
have screened for similarities or differences among BM-
MSCs and UC-MSCs at the molecular level [31, 32]. In addi-
tion, a previous report demonstrated that migration of UCB-
MSC towards glioma cells was higher when compared to
BM-MSCs likely due to increased levels of the IL-8 receptor,
CXCR1, and CXCR2 in the former cell type [18]. In contrast
to these observations, we found that HUCPVCs presented
lower levels of CXCR1 and CXCR2 expression compared to
BM-MSCs and these differences could be explained partially
due to differences in tissue source and culture conditions and
merit further investigation.The analysis of IL-6R and IL6-ST
expression showed similar levels in both types ofMSCs, while
levels of MCP-1 receptor (CCR2) were slightly increased in
HUCPVCs. Interestingly, we found that not only AMFR but
also CAV-1 and CAV-2, which are genes that regulate the
availability of AMFR on cell surface [33], were overexpressed
in HUCPVCs compared to BM-MSCs. In line with this, a
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reduced expression level of IGFBP3, a protein which can
bind to AMF blocking its binding to AMFR [34], was found
in HUCPVCs when compared to BM-MSCs. Moreover, an
increased expression of MMP3 was observed in HUCPVCs.
This matrix metalloproteinase is involved in AMF-induced
migration and it is necessary for cell invasion and proteolysis
of the extracellularmatrix [35]. Finally, and consistentwith an
increase in the expression of genes related to the AMF/AMFR
pathway, not only HUCPVCs show an enhanced in vitro
migration towards rAMF, but also the specific blockage
of AMF in HC-PT-5 TCM was able to reduce HUCPVCs
migration to a greater level when compared to BM-MSCs.
The potential use of MSCs in cancer treatment as carriers
of therapeutic genes has raised some concerns about the
safety of their use in the clinic. There are some studies
that indicated that MSCs have protumorigenic capacity
due to their immunosuppression properties, modulation of
the epithelial-to-mesenchymal transition, and induction of
angiogenesis [36]. However, others have demonstrated that
MSCs decreased HCC growth [37, 38]. Similarly, we have
previously demonstrated that BM-MSCs did not modify
tumor growth in vivo [25]. Moreover, we observed that
HUCPVCs did not induce tumor growth when injected i.v.
in Huh7 s.c. tumor-bearing mice (data not shown). The
use of HUCPVCs as cellular carriers could also have the
advantage of its allogeneic application because of its low
immunogenicity [9]. In this regard, HUCPVCs could be
useful as carriers of therapeutic genes for cancer patients,
where isolation of BM or adipose tissue-derived MSCs could
be less responsive to chemotactic factors, and might dis-
play higher immunosuppression capacities than MSCs from
healthy donors [39] or even present genetic abnormalities.
5. Conclusions
In summary, our results demonstrate a greater migration
capacity to HCC of HUCPVCs when compared to BM-
MSCs not only in vitro but also in vivo, likely due to an
increase in migratory response to AMF and to an enhanced
adhesive capacity to tumor microvasculature. Considering
their availability and that no invasive procedures are required
to obtain HUCPVCs, these cells have advantages over BM-
MSCs as candidates for carriers of therapeutic genes for the
treatment of HCC.
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